Elicio Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Elicio Therapeutics, Inc. (ELTX) reported Increase (Decrease) in Accounts Payable of $167.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Elicio Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $627.00K.
- Elicio Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$460.00K, a 115.34% decline year-over-year.
- Elicio Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $351.00K.
- Elicio Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$3.54M, a 481.49% decline year-over-year.
- Elicio Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$366.00K.
- Elicio Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$3.33M, a 14582.61% decline from fiscal 2023.
- Elicio Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $23.00K, a 97.96% decline from fiscal 2022.
- Elicio Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.13M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $627.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $167.00K 10-Q · filed 2026-08-13 | $518.00K derived: sum of 3 quarters · filed 2026-08-13 | -$3.03M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$460.00K 10-Q · filed 2026-05-11 | -$109.00K derived: sum of 2 quarters · filed 2026-05-11 | -$3.65M derived: sum of 3 quarters · filed 2026-05-11 | -$3.83M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$3.19M derived: sum of 2 quarters · filed 2026-03-12 | -$3.37M derived: sum of 3 quarters · filed 2026-08-13 | -$366.00K 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.72M derived: sum of 2 quarters · filed 2026-08-13 | -$717.00K 10-Q · filed 2025-11-13 | -$1.66M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.83M 10-Q · filed 2026-08-13 | $1.88M derived: sum of 3 quarters · filed 2026-08-13 | $2.81M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-11 | $2.05M derived: sum of 2 quarters · filed 2026-05-11 | $2.98M derived: sum of 3 quarters · filed 2026-05-11 | $2.93M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$17.00K derived: sum of 2 quarters · filed 2026-03-12 | -$67.00K derived: sum of 3 quarters · filed 2026-03-12 | -$3.33M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $929.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $879.00K derived: sum of 2 quarters · filed 2025-11-13 | -$2.38M 10-Q · filed 2025-11-13 | -$2.42M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$3.31M 10-Q · filed 2025-08-07 | -$3.35M derived: sum of 3 quarters · filed 2025-08-07 | -$3.21M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$3.26M 10-Q · filed 2025-05-13 | -$3.30M derived: sum of 2 quarters · filed 2025-05-13 | -$3.16M derived: sum of 3 quarters · filed 2025-05-13 | -$4.63M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $102.00K derived: sum of 2 quarters · filed 2025-03-31 | -$1.36M derived: sum of 3 quarters · filed 2025-03-31 | $23.00K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.32M derived: sum of 2 quarters · filed 2024-11-13 | $63.00K 10-Q · filed 2024-11-13 | -$219.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$79.00K 10-Q · filed 2024-08-13 | -$361.00K derived: sum of 3 quarters · filed 2024-08-13 | -$713.00K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $1.39M 10-Q · filed 2024-05-15 | -$1.83M 10-Q · filed 2023-05-10 | $1.10M derived: sum of 2 quarters · filed 2024-05-15 | $751.00K derived: sum of 3 quarters · filed 2024-05-15 | $3.83M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$634.00K derived: sum of 2 quarters · filed 2024-03-29 | $2.45M derived: sum of 3 quarters · filed 2024-03-29 | $1.13M 10-K · filed 2024-03-29 | -$2.05M 10-K · filed 2023-03-17 | |||
| 2022-09-30 | -$352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.73M derived: sum of 2 quarters · filed 2023-11-13 | $1.41M 10-Q · filed 2023-11-13 | -$2.53M 10-Q · filed 2022-11-14 | -$1.53M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.76M 10-Q · filed 2023-08-14 | -$2.09M 10-Q · filed 2022-08-15 | -$1.18M derived: sum of 3 quarters · filed 2023-08-14 | -$2.84M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$1.32M 10-Q · filed 2023-05-10 | -$4.26M derived: sum of 2 quarters · filed 2023-05-10 | -$5.92M derived: sum of 3 quarters · filed 2023-05-10 | -$3.30M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$4.60M derived: sum of 2 quarters · filed 2023-03-17 | -$1.98M derived: sum of 3 quarters · filed 2023-03-17 | -$866.00K 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $960.00K derived: sum of 2 quarters · filed 2022-11-14 | $2.07M 10-Q · filed 2022-11-14 | $3.00M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $3.74M 10-Q · filed 2022-08-15 | $4.66M derived: sum of 3 quarters · filed 2022-08-15 | -$7.69M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $1.11M 10-Q · filed 2022-05-16 | $2.04M derived: sum of 2 quarters · filed 2022-05-16 | -$10.31M derived: sum of 3 quarters · filed 2022-05-16 | -$5.94M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $923.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$11.42M derived: sum of 2 quarters · filed 2022-03-30 | -$7.05M derived: sum of 3 quarters · filed 2022-03-30 | -$5.61M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | -$12.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$7.97M derived: sum of 2 quarters · filed 2021-11-12 | -$6.53M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $4.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $5.82M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $1.45M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |